Page results
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
This page explains what patient-initiated follow-up (PIFU) involves after your treatment for endometrial (uterine or womb) cancer.
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
-
This page explains the Rafaelo™ procedure, a treatment for haemorrhoids, which are also known as piles.
-
Trial of T-cell therapy for lung cancer begins at UCLH
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
Having proton beam therapy under general anaesthetic: information for children aged 5-8 patient information
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
File results
-
FOI/2022/0169 - Strategic workforce plan for recruitment and retention of Allied Health Professions
-
FOI/2022/0171 - Consultant-led Referral to Treatment (RTT), outpatients and Patient Initiated Follow-up (PIFU)
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients